- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Senate passes Drug Quality and Security Act
- Reports: ESI may start 'price war' over new hepatitis C drugs
- Roxane Labs' generic prostate drug gets tentative approval from FDA
NEW YORK — The generic drug user fee program may have hit a speed bump due to budget problems in Congress, according to published reports.
Bloomberg reported that implementation of the law may be delayed because Congress must first pass legislation authorizing the Food and Drug Administration to collect money from generic drug companies, but the problem is that members of Congress will leave Washington this week, not to return until after the Nov. 6 elections.
The Generic Drug User Fee Amendments, part of the renewal of PDUFA that president Barack Obama signed in July, will collect $299 million per year in user fees from generic drug companies over the next five years starting on Oct. 1. This, drug makers and agency officials hope, will help the FDA reduce a backlog of more than 2,000 generic drug approval applications and ensure faster review of future applications.